







an Open Access Journal by MDPI

## **Marine Chitin 2019**

Guest Editors:

### Dr. Hitoshi Sashiwa

Kaneka Co., Ltd, 5-1-1 Torikai-Nishi, Settsu, Osaka 566-0072, Japan

#### Dr. Hironori Izawa

Department of Chemistry and Biotechnology, Graduate School of Engineering, Tottori University, Tottori, 680-8552, Japan

Deadline for manuscript submissions:

closed (31 December 2019)

# **Message from the Guest Editors**

Dear Colleagues,

As results of our calls in 2014–2018 for submissions to Special Issues related to Chitin and Chitosan in *Marine Drugs*, we are pleased to tell you that these issues were published as books. A number of high class papers were included in these issues. Because of these successes, we now seek to publish a Special Issue, "Marine Chitin, 2019" in *Marine Drugs*. As before, we plan to produce a strong, and very exciting issue that will encompass breakthroughs in high value, scientific and industrial chitin and chitosan research. Despite significant advances in chitin and chitosan research since the 1970s, current overviews in recent publications involving chitin and chitosan research advances need reporting.

We look forward to your input.

Dr. Hitoshi Sashiwa Dr. Hironori Izawa Guest Editors













an Open Access Journal by MDPI

## **Editor-in-Chief**

### Prof. Dr. Bill J. Baker

Department of Chemistry, University of South Florida, 4202 E. Fowler Ave., CHE 205, Tampa, FL 33620-5250, USA

# **Message from the Editor-in-Chief**

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

### **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, MarinLit, AGRIS, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmacology, Toxicology and Pharmaceutics (miscellaneous))

#### **Contact Us**